Trials / Completed
CompletedNCT03444701
A Study of E7130 in Participants With Solid Tumors
A Phase 1 Study of E7130 in Subjects With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7130 | Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1. |
| DRUG | E7130 | Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1. |
Timeline
- Start date
- 2018-02-05
- Primary completion
- 2024-12-27
- Completion
- 2024-12-27
- First posted
- 2018-02-23
- Last updated
- 2025-03-06
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03444701. Inclusion in this directory is not an endorsement.